Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials.
暂无分享,去创建一个
Kurt Ulm | Adnan Kastrati | Albert Schömig | A. Kastrati | J. Mehilli | A. Schömig | K. Ulm | J. Suárez de Lezo | Julinda Mehilli | José Suárez de Lezo | A. Dibra | Alban Dibra | Sonja Eberle | Jean-Jacque Goy | S. Eberle | J. Goy
[1] C. Rogers. Drug-eluting stents: clinical perspectives on drug and design differences. , 2005, Reviews in cardiovascular medicine.
[2] F. Eberli,et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.
[3] M. Egger,et al. The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.
[4] Gregg W. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .
[5] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[6] Lawrence Joseph,et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents , 2004, The Lancet.
[7] J. Nawarskas,et al. Paclitaxel-eluting stents in coronary artery disease. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[8] Chen Ji-ya. ISAR-DIABETES: Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Stent for the Prevention of Restenosis in Diabetic Patients with Coronary Artery Disease , 2006 .
[9] D. Faxon. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices. , 2005, Reviews in cardiovascular medicine.
[10] M. Krucoff,et al. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. , 2005, Journal of the American College of Cardiology.
[11] William Wijns,et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.
[13] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[14] M. Hadamitzky,et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.
[15] D G Altman,et al. Concealing treatment allocation in randomised trials , 2001, BMJ : British Medical Journal.
[16] Douglas G Altman,et al. Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.
[17] J. Stauffer,et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. , 2005, Journal of the American College of Cardiology.
[18] M. Hadamitzky,et al. Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.
[19] E. Perin. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS. , 2005, Reviews in cardiovascular medicine.
[20] Patrick W Serruys,et al. New frontiers in cardiology: drug-eluting stents: Part I. , 2003, Circulation.
[21] B. Gersh. Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents , 2006 .
[22] George Davey Smith,et al. Meta-analysis: Principles and procedures , 1997, BMJ.
[23] A. Kastrati,et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. , 2005, The New England journal of medicine.
[24] B. Gersh. Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis: A Randomized Controlled Trial , 2006 .
[25] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[26] E. Edelman,et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] Gregg W Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[28] M. Rothman,et al. Antiproliferative coatings for the treatment of coronary heart disease:. what are the targets and which are the tools? , 2003, Journal of interventional cardiology.
[29] New Frontiers in Cardiology Drug-Eluting Stents: Part II Clinical Cardiology: New Frontiers , 2022 .
[30] S Greenland,et al. Invited commentary: a critical look at some popular meta-analytic methods. , 1994, American journal of epidemiology.
[31] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[32] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[33] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[34] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[35] Ciro Indolfi,et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. , 2004 .